$-0.46 EPS Expected for Genocea Biosciences (GNCA); Lakeland Industries (LAKE)’s Sentiment Is 2.57

July 17, 2017 - By Nellie Frank

Lakeland Industries, Inc. makes and sells a line of safety garments and accessories for the industrial and public protective clothing market. The company has market cap of $122.58 million. The Company’s product categories include limited use/disposable protective clothing; high-end chemical protective suits; firefighting, flame resistant personal protective equipment (FR PPE) and heat protective apparel; reusable woven garments; high visibility clothing, and glove and sleeves. It has a 21.25 P/E ratio. The Company’s products are sold by its in-house customer service group, its regional sales managers and independent sales representatives to a network of over 1,200 North American safety and mill supply distributors.

Analysts expect Genocea Biosciences Inc (NASDAQ:GNCA) to report $-0.46 EPS on August, 3.They anticipate $0.07 EPS change or 17.95% from last quarter’s $-0.39 EPS. After having $-0.48 EPS previously, Genocea Biosciences Inc’s analysts see -4.17% EPS growth. About 78,787 shares traded. Genocea Biosciences Inc (NASDAQ:GNCA) has risen 67.22% since July 17, 2016 and is uptrending. It has outperformed by 50.52% the S&P500.

Among 4 analysts covering Genocea Biosciences (NASDAQ:GNCA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Genocea Biosciences had 7 analyst reports since August 6, 2015 according to SRatingsIntel. Needham maintained Genocea Biosciences Inc (NASDAQ:GNCA) rating on Thursday, September 29. Needham has “Buy” rating and $15 target. The firm has “Overweight” rating given on Thursday, September 29 by PiperJaffray. Needham maintained the stock with “Buy” rating in Tuesday, August 11 report. Needham maintained the stock with “Buy” rating in Tuesday, October 20 report. The firm earned “Buy” rating on Thursday, December 17 by UBS. FBR Capital maintained Genocea Biosciences Inc (NASDAQ:GNCA) rating on Monday, October 19. FBR Capital has “Outperform” rating and $17 target. Piper Jaffray maintained the stock with “Overweight” rating in Thursday, August 6 report.

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The company has market cap of $141.10 million. The Firm uses its discovery platform, AnTigen Lead Acquisition System , to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. It currently has negative earnings. The Firm has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes.

Parthenon Llc holds 0.42% of its portfolio in Lakeland Industries, Inc. for 165,763 shares. First Wilshire Securities Management Inc owns 93,705 shares or 0.28% of their US portfolio. Moreover, Morgan Dempsey Capital Management Llc has 0.28% invested in the company for 95,030 shares. The Us-based Ancora Advisors Llc has invested 0.22% in the stock. Tfs Capital Llc, a Pennsylvania-based fund reported 11,403 shares.

About 236,425 shares traded or 164.57% up from the average. Lakeland Industries, Inc. (LAKE) has risen 32.68% since July 17, 2016 and is uptrending. It has outperformed by 15.98% the S&P500.